Washington, DC 11/5/12; Washington, DC 12/28/12—Singulex has withdrawn its filing for an IPO (see IBO 10/15/12) on the New York Stock Exchange, citing current marketplace conditions. Singulex provides immunoassay technology for life science research and diagnostics. The company had intended to publicly offer 4,375,000 shares at a price of $15–$17 per share for net proceeds of approximately $62.3 million.